bilaterals.org logo
bilaterals.org logo

India FTAs & medicines


India-UK FTA leaked draft reveals nobody’s gain except big pharma
India - UK FTA provisions favor neither India nor the UK except the pharma industry in a big way. It defeats the firm stand taken by the Indian PM three years ago when he decided to pull out of the RCEP against the corporate interests over people’s lives.
MSF responds to UK’s disastrous proposal on intellectual property in UK-India Free Trade Agreement
UK IP demands contain provisions that would drastically harm access to affordable, lifesaving generic medicines from India, upon which millions of people around the world rely.
After India-Aus FTA, Indian pharma industry sees global opportunities
After the Comprehensive Economic Cooperation Agreement signed between India and Australia, the domestic pharmaceutical industry is seeing a plethora of opportunities for international trade.
An India-UK trade deal could mean a race to the bottom for Indian workers
On farmers and food, vaccine inequality, climate justice and digital rights, we need to act in solidarity – and not allow trade rules to sacrifice people to corporate profit.
World has moved on from US, EU’s drug monopoly. India and China are changing IP regulations
Even without an IP waiver from the WTO, China and India are leading the challenge to the West’s vaccine monopoly.
TRIPS Waiver: A BIT of a challenge for India
Potential BIT claims by foreign pharmaceutical companies against India for the revocation, suspension or non-enforcement of IPRs could undermine the benefits of a potential TRIPS waiver.
India, US trade deal: New Delhi seeks preferential treatment on drugs, other goods
India is seeking concessions for generic drugs it exports to the United States in return for opening its dairy markets and slashing tariffs on farm goods as the two sides seek to shore up a new trade deal.
Covid-19: Why India doesn’t need to worry about investor-State dispute settlement claims
In order to halt the spread of the coronavirus pandemic (Covid-19) and to boost the public health care system and preparedness, India has taken several regulatory steps.
Can a US-India trade deal permanently alter the way Indians access medicines?
US-India IP engagements since 2006 have served the interests of the US through systematic undermining of the legislative safeguards in the Indian Patents Act.
India, Indonesia negotiating economic cooperation agreement
India and Indonesia are set to launch negotiations for a Comprehensive Economic Cooperation Agreement (CECA) to cover economic cooperation while trading in goods, services, and investments.
As Modi visits US, what does the free trade pact mean for India’s pharma industry?
A Free Trade Agreement with the US will likely result in the amendment of the Patents Act, which could impact the Indian pharma industry.
MSF statement on resumption of EU-India FTA negotiations
Officials from the European Union (EU) and India are expected to meet in Brussels on April 12th to resume technical talks on the long-stalled EU-India free trade agreement (FTA). A leaked draft of the agreement, which has been under discussion since 2007, contains proposals from the EU that push for intellectual property (IP) provisions in the FTA that could jeopardize access to affordable medicines.
Delhi’s RCEP talks on intellectual property shouldn’t forget India’s role as ‘Pharmacy of the World’
India must resist pressure from Japan and South Korea in RCEP for the elevated levels of intellectual property provisions and make sure the deal doesn’t limit the production of life-saving generic drugs in India and for many other developing countries of the world.
India-Cambodia deliberates on financial support in agriculture, pharmaceuticals
India and Cambodia clinch a deal to work towards a Bilateral Investment Treaty which provides financial help to Southeast Asian nations.
FTA with Peru: India may have to lower import duty on drugs
India may have to lower the import duty on pharmaceuticals for Peru in the discussions on the proposed free trade agreement (FTA) with the South American country.
Israel set to make a strong push for goods FTA
The present Indian government has relaunched the talks with Israel. Israel wishes to conduct talks on regular basis to conclude the deal at the earliest. Indian patent system and pharmaceutical related issues have been the reasons why the deal couldn’t progress.
RCEP: India in a Catch-22
India’s position in the RCEP is the most protectionist among all the member nations. India has been resisting demands from Korea & Japan on intellectual property clauses, and other nations on opening up markets.
As India set to sign FTA with Peru, govt seeks industry views on export import duty rates
If the trade equation between India and Peru is in imbalance it would be causing more harm than benefit to India.
India to oppose anti-generics proposals at RCEP meet
India firm in opposing proposals that could hinder global access to affordable generic drugs
India will not cross red lines on generic drugs in RCEP, but stay vigilant, say officials
Healthcare watchers are calling on India to resist RCEP